Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer.

  PMID 42193276 · PMC13203762 · Biomedicines · 2026 · 8 claims · 8 setups

  Full-text index only

  PARPi + ARPi combinations are effective in ARPi-sensitive (C4-2B) and ARPi-resistant (AbiR, MDVR) prostate cancer models, but provide the greatest benefit in ARPi-sensitive cells

  c4-2b cck-8 morphology western

• MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer.

  PMID 41529070 · PMC13136877 · Cancer research · 2026 · 7 claims · 8 setups

  Full-text index only

  EVI1, encoded by MECOM, is an AR-recruited coactivator of noncanonical AR signaling in prostate cancer.

  lrex lucap167 prostate live-cell spheroid patient-derived